How are NovaBridge Biosciences (NBP) Ordinary Shares related to its ADSs in this Form 4?

The filing states that NovaBridge Biosciences’ Ordinary Shares may be represented by ADSs, where each 10 ADSs represent 23 Ordinary Shares. Several reported amounts in the Form 4 are expressed in terms of ADSs and then related to Ordinary Shares using this ratio.

NovaBridge EVP sells 3,282 shares at $0.79

Q: What insider transactions did NBP executive Xu Cong Claire report in this Form 4?

Xu Cong Claire reported exercising 4,079 restricted share units into 9,382 Ordinary Shares on August 30, 2026, increasing her direct Ordinary Share holdings to 28,558, and then selling 3,282 Ordinary Shares on August 31, 2026 in an open-market or private transaction.

Q: How many NovaBridge Biosciences (NBP) shares did Xu Cong Claire sell and at what price?

She sold 3,282 Ordinary Shares of NovaBridge Biosciences on August 31, 2026 at a reported price of $0.79 per Ordinary Share, which corresponds to a converted ADS sales price of $1.8186 per American Depositary Share.

Q: What RSU activity did NBP report for Xu Cong Claire in this filing?

The filing shows the exercise of 4,079 restricted stock units (RSUs) on August 30, 2026. Each RSU represents a contingent right to receive one ADS, and the exercised RSUs correspond to 9,382 Ordinary Shares of NovaBridge Biosciences.

EVP Clinical Development Xu Cong Claire exercised 4,079 RSUs to lift holdings, then sold 3,282 Ordinary Shares for $0.79 each.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

NovaBridge Biosciences (NBP) executive Xu Cong Claire, EVP Clinical Development, reported a set of related equity transactions. On August 30, 2026, 4,079 restricted share units were exercised into 9,382 Ordinary Shares, increasing direct holdings of Ordinary Shares to 28,558. On August 31, 2026, she then sold 3,282 Ordinary Shares in a sale in the open market or a private transaction at $0.79 per share, with the reported sales price corresponding to an ADS price of $1.8186.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Xu Cong Claire

Role EVP, Clinical Development

Sold 3,282 shs ($3K)

Approx. gross sale proceeds $3K

Type	Security	Shares	Price	Value
Sale	Ordinary Shares ^{F1, F5, F6, F7}	3,282	$0.79	$3K
Exercise	Restricted Share Units ^{F3, F8, F9, F1}	4,079	$0.00	$0.00
Exercise	Ordinary Shares ^{F1, F2, F3, F4}	9,382	--	--

Holdings After Transaction: Restricted Share Units — 28,558 contracts (Direct); Ordinary Shares — 304,201 shares (Direct)

Footnotes (9)

F1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
F2. Reported securities are represented by 4,079 ADSs.
F3. Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
F4. Reported securities are represented by 133,688 ADSs.
F5. Reported securities are represented by 1,427 ADSs.
F6. Reported sales price represents the converted sales price of the ADSs of $1.8186.
F7. Reported securities are represented by 132,261 ADSs.
F8. Reported securities represent ADSs.
F9. On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.

Key Figures

Ordinary Shares sold: 3,282 Ordinary Shares Sale price per Ordinary Share: $0.79 per share ADS sales price: $1.8186 per ADS +5 more

8 metrics

Ordinary Shares sold 3,282 Ordinary Shares Sale transaction on 2026-08-31

Sale price per Ordinary Share $0.79 per share Converted from ADS sale price on 2026-08-31

ADS sales price $1.8186 per ADS Reported converted sales price of the ADSs

RSUs exercised 4,079 RSUs Exercise of restricted share units on 2026-08-30

Ordinary Shares from RSU exercise 9,382 Ordinary Shares Underlying shares from 4,079 RSUs on 2026-08-30

Ordinary Shares held after RSU exercise 28,558 Ordinary Shares Direct holdings reported following the RSU-related transaction

RSU grant size 65,270 RSUs RSUs granted on May 30, 2024 vesting over four years

ADS to Ordinary Share ratio 10 ADSs represent 23 Ordinary Shares Relationship between ADSs and Ordinary Shares

Key Terms

American Depositary Shares ("ADSs"), restricted stock unit ("RSU"), contingent right

3 terms

American Depositary Shares ("ADSs") financial

"The Ordinary Shares may be represented by American Depositary Shares ("ADS")."

American Depositary Shares (ADSs) are U.S.-listed certificates issued by a bank that represent ownership of a specified number of a foreign company’s ordinary shares, letting U.S. investors buy and sell those interests in U.S. dollars on American markets. They matter because they make investing in overseas companies as easy as buying a domestic stock—streamlining currency, settlement, and recordkeeping—while still exposing investors to foreign-market risks like exchange rates and local regulations.

restricted stock unit ("RSU") financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one ADS."

contingent right financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one ADS."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did NBP executive Xu Cong Claire report in this Form 4?

Xu Cong Claire reported exercising 4,079 restricted share units into 9,382 Ordinary Shares on August 30, 2026, increasing her direct Ordinary Share holdings to 28,558, and then selling 3,282 Ordinary Shares on August 31, 2026 in an open-market or private transaction.

How many NovaBridge Biosciences (NBP) shares did Xu Cong Claire sell and at what price?

She sold 3,282 Ordinary Shares of NovaBridge Biosciences on August 31, 2026 at a reported price of $0.79 per Ordinary Share, which corresponds to a converted ADS sales price of $1.8186 per American Depositary Share.

What RSU activity did NBP report for Xu Cong Claire in this filing?

The filing shows the exercise of 4,079 restricted stock units (RSUs) on August 30, 2026. Each RSU represents a contingent right to receive one ADS, and the exercised RSUs correspond to 9,382 Ordinary Shares of NovaBridge Biosciences.

What were Xu Cong Claire’s reported NovaBridge Biosciences holdings after the RSU exercise?

After the August 30, 2026 RSU-related transaction, Xu Cong Claire was reported as directly holding 28,558 Ordinary Shares of NovaBridge Biosciences. This figure reflects her Ordinary Share position following the exercise of 4,079 RSUs into 9,382 Ordinary Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/01/2026 - 06:00 PM EDT Accepted by SEC EDGAR 09/01/2026 - 06:00 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xu Cong Claire

(Last)

(First)

(Middle)

C/O NOVABRIDGE BIOSCIENCES

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Clinical Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	08/30/2026		M		9,382⁽²⁾	A	⁽³⁾	307,483⁽⁴⁾	D
Ordinary Shares⁽¹⁾	08/31/2026		S		3,282⁽⁵⁾	D	$0.79⁽⁶⁾	304,201⁽⁷⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Share Units	⁽³⁾	08/30/2026		M			4,079⁽⁸⁾	⁽⁹⁾	⁽⁹⁾	Ordinary Shares⁽¹⁾	4,079⁽⁸⁾	$0	28,558	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. Reported securities are represented by 4,079 ADSs.

3. Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.

4. Reported securities are represented by 133,688 ADSs.

5. Reported securities are represented by 1,427 ADSs.

6. Reported sales price represents the converted sales price of the ADSs of $1.8186.

7. Reported securities are represented by 132,261 ADSs.

8. Reported securities represent ADSs.

9. On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.

	/s/ Kyler Lei, Attorney-in-Fact	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR